CRS3123   Click here for help

GtoPdb Ligand ID: 10991

Synonyms: CRS-3123 | REP-3123 | REP3123
PDB Ligand
Compound class: Synthetic organic
Comment: CRS3123 is an orally bioactive, diaryldiamine compound that inhibits bacterial methionyl-tRNA synthetases in Gram-positive bacteria [1]. It has limited antibacterial activity against normal anaerobic gut flora (e.g. Clostridium ramosum, bifidobacteria, lactobacilli of the Lactobacillus casei-rhamnosus-plantarum group) and Gram-negative anaerobes.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 94.39
Molecular weight 510.96
XLogP 6.05
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Brc1cc(Br)c2c(c1)[C@H](NCCCNc1cc(=O)c3c([nH]1)ccs3)CCO2
Isomeric SMILES Brc1cc(Br)c2c(c1)[C@H](NCCCNc1cc(=O)c3c([nH]1)ccs3)CCO2
InChI InChI=1S/C19H19Br2N3O2S/c20-11-8-12-14(2-6-26-18(12)13(21)9-11)22-4-1-5-23-17-10-16(25)19-15(24-17)3-7-27-19/h3,7-10,14,22H,1-2,4-6H2,(H2,23,24,25)/t14-/m1/s1
InChI Key NNTYBKTXMKBRFA-CQSZACIVSA-N
No information available.
Summary of Clinical Use Click here for help
CRS3123 has completed Phase 1 evaluation [2-3] and has begun Phase 2 development for the treatment of C. difficile infection.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04781387 Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection Phase 2 Interventional Crestone, Inc
NCT01551004 Phase I Trial of a Single Dose of CRS3123 Phase 1 Interventional National Institute of Allergy and Infectious Diseases (NIAID) A dose escalation study to assess the safety, tolerability and systemic exposure of a single oral dose of CRS3123 in healthy adults. The results support further clinical development of CRS3123 as a treatment for C. difficile infection. 3
NCT02106338 Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123. Phase 1 Interventional National Institute of Allergy and Infectious Diseases (NIAID) A multiple-ascending dose study to assess the safety, tolerability and pharmacokinetics of CRS3123 in healthy adults. The results support further clinical development of CRS3123 as a treatment for C. difficile infection. 2